Upon failure of first-line ADT, should second-line hormonal manipulation without survival benefit data still be used?
Main Authors: | Bannakij Lojanapiwat, Masatoshi Eto, Paul Mainwaring |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-12-01
|
Series: | Prostate International |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2287888215300933 |
Similar Items
-
Infective complication following percutaneous nephrolithotomy
by: Bannakij Lojanapiwat
Published: (2016-03-01) -
Noninvasive Assessment of Patency of Internal Ureteral Stent: Role of Colour Doppler Ultrasound
by: Bannakij Lojanapiwat
Published: (2004-10-01) -
Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice
by: Bannakij Lojanapiwat
Published: (2014-09-01) -
The ideal puncture approach for PCNL: Fluoroscopy, ultrasound or endoscopy?
by: Bannakij Lojanapiwat
Published: (2013-01-01) -
Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
by: Tobias Engel Ayer Botrel, et al.
Published: (2016-01-01)